Obeticholic acid prevents cyclophosphamide-induced placental injury via SIRT1 and TLR4/NF-κB pathways [PDF]
BMC Pharmacology and ToxicologyBackground The aim of the current study is to identify the possible protective effect of obeticholic acid (OCA) on placental injury caused by cyclophosphamide (CP). OCA was administered in the presence and absence of CP.
Walaa Yehia Abdelzaher +9 more
doaj +2 more sources
Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease [PDF]
Biology Direct, 2023 The response rate to obeticholic acid (OCA), a potential therapeutic agent for non-alcoholic fatty liver disease, is limited. This study demonstrated that upregulation of the alternative bile acid synthesis pathway increases the OCA treatment response ...
Seung Min Lee +8 more
doaj +2 more sources
Obeticholic acid: expanding the therapeutic landscape of NASH
Annals of Hepatology, 2015 Currently treatment options for Non-Alcoholic Steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease (NAFLD) and one of the commonest causes of cirrhosis worldwide, are mainly limited to promotion of life style changes in diet and exercise habits as well as to control of comorbidities such as type 2 diabetes mellitus and ...
Marco Arrese +2 more
doaj +3 more sources
Effects of Obeticholic Acid Treatment on Primary Human Hepatocytes in a Novel Tri-Culture Model System [PDF]
CellsMetabolic dysfunction-associated fatty liver disease (MAFLD) is a growing health concern worldwide. Human cell-based in vitro culture models that retain disease-relevant phenotypic pathways and responses to assess the efficacy and liability of new ...
Justin J. Odanga +5 more
doaj +2 more sources
Protective Effect of Obeticholic Acid on Sepsis-Induced Liver Dysfunction via Regulating Bile Acid Homeostasis [PDF]
PharmaceuticalsBackground/Objectives: Abnormal bile acid (BA) pool may play an important role in inducing liver damage in sepsis. Farnesoid X receptor (FXR) is a main negative feedback regulator of BA metabolism.
Jiahui Wang +5 more
doaj +2 more sources
Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway [PDF]
Frontiers in Immunology, 2022 Hepatocellular carcinoma (HCC) is the most common type of liver malignancy with a high incidence and mortality rate. Previous in vitro and in vivo studies have confirmed that liver sinusoidal endothelial cells (LSEC) secrete CXCL16, which acts as a ...
Haoxian Gou +9 more
doaj +2 more sources
Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis [PDF]
Liver Research, 2022 Background and aims: Several bile acids-based monotherapies have been developed for non-alcoholic steatohepatitis (NASH) treatment but clinical trial findings suggest that they do not satisfactorily improve NASH and liver fibrosis in many patients ...
David J. Matye +6 more
doaj +2 more sources
Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters [PDF]
Journal of Lipid Research, 2017 The farnesoid X receptor (FXR) plays critical roles in plasma cholesterol metabolism, in particular HDL-cholesterol (HDL-C) homeostasis. Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. Previous studies
Bin Dong +4 more
doaj +3 more sources
Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy [PDF]
PharmaceuticsObjective: Liver fibrosis, a hallmark of chronic liver diseases, is characterized by excessive extracellular matrix (ECM) deposition and scar tissue formation.
Yawen Wang +6 more
doaj +2 more sources
Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. [PDF]
Clin Liver Dis (Hoboken), 2021 Ratziu V.
europepmc +4 more sources